
Spanberger calls for Congress to address frightening new U.S. deficit numbers
Abigail Spanberger is sounding the alarm about scary new numbers from the U.S. Treasury Department showing a ballooning federal deficit and a massive national debt.

Abigail Spanberger is sounding the alarm about scary new numbers from the U.S. Treasury Department showing a ballooning federal deficit and a massive national debt.

The House Foreign Affairs Committee passed Rep. Abigail Spanberger’s legislation to protect 5G telecommunications systems and mobile infrastructure.

The House Agriculture Committee today passed Rep. Abigail Spanberger’s bipartisan legislation to protect agribusinesses in the wake of commodity broker bankruptcies.

The House today voted 403 to zero to pass Rep. Abigail Spanberger’s bipartisan bill to help tackle the prescription drug affordability crisis and bring greater transparency to prescription drug negotiations.

Abigail Spanberger helped introduce legislation to give rural communities new, flexible funding for local economic development projects.

Abigail Spanberger led a bipartisan letter with 48 of her House colleagues calling on the Senate and House to prioritize funding to support high-speed broadband internet infrastructure projects across rural America.

Following President Trump’s announcement that the administration will be lifting all sanctions on Turkey, Rep. Abigail Spanberger questioned the administration’s erratic strategy behind the U.S. withdrawal from Northern Syria.

Abigail Spanberger voted with a majority of the House of Representatives to pass legislation that would strengthen efforts to combat and prevent foreign interference in U.S. elections.

Abigail Spanberger led a House Agriculture Committee’s Subcommittee on Conservation and Forestry hearing on Tuesday focused on expanding the financial and conservation benefits of precision agriculture technology.

Rep. Abigail Spanberger today introduced bipartisan legislation to increase access to lower-cost prescription drugs and stop harmful practices that block new generic alternatives from entering the consumer market.
We don’t take press releases or official statements as the final word. Digging in to get the whole story takes time and resources.